Sign In
Buy ORTX
$16.70
+0 (+0%)
At Close: Mar 15, 2024
Orchard Therapeutics: Cutting-Edge Science Beset With A Pioneer's Typical Hurdles
07:31am, Monday, 16'th Aug 2021
ORTX is a developer of autologous gene therapies for rare diseases.
Orchard Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Business Updates
07:00am, Wednesday, 04'th Aug 2021
Regulatory feedback obtained on OTL-200 (MLD) and OTL-203 (MPS-IH) programs
Orchard Therapeutics, Pharming Ink Development Pact For Gene Therapy
10:35am, Thursday, 01'st Jul 2021
Orchard Therapeutics plc (NASDAQ: ORTX) and Pharming Group NV (NASDAQ: PHAR) have collaborated to research, develop, manufacture and commercialize OTL-105 for hereditary angioedema (HAE). OTL-10
Highlights the broader potential of Orchard's ex vivo HSC gene therapy platform approach in new and larger indications
Orchard Therapeutics Issues Updates On Gene Therapy Programs
11:43am, Tuesday, 29'th Jun 2021
Orchard Therapeutics plc (NASDAQ: ORTX) has provided updates on the progress of its lead gene therapy programs targeting metachromatic leukodystrophy (MLD), mucopolysaccharidosis type I Hurler synd
Orchard Therapeutics Posts Long-Term Data For Gene Therapy In Inherited Immune System Disorder
01:06pm, Tuesday, 11'th May 2021
Three years after receiving gene therapy from Orchard Therapeutics (NASDAQ: ORTX) in an early-stage clinical trial, 100% of patients with an inherited disease that damages the immune system were stil
Orchard Therapeutics Announces Multiple Presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy
07:01am, Wednesday, 28'th Apr 2021
Seven abstracts accepted show the potential of HSC gene therapy to transform the treatment of multiple severe rare disorders
Orchard Therapeutics: Curative Medicines For Immune-Related Diseases
12:18pm, Wednesday, 24'th Mar 2021
Orchard Therapeutics is the category leader for engineering and developing hematopoietic stem cell medicines. The company's platform has been validated with 2 approvals in Europe and a diverse pipelin
Regenerative Medicine Attracted Record $20 Billion in Funding in 2020
02:15pm, Tuesday, 23'rd Mar 2021
Cell and gene therapy companies are quickly emerging as favorites of venture capital firms, investors and members of Big Pharma, according to a report from the Alliance for Regenerative Medicine.
Rocket Pharmaceuticals Primed for Takeoff
06:19pm, Monday, 15'th Mar 2021
With all due respect to Elton John, the real Rocket Man is in Cranbury, New Jersey.
Recap: Orchard Therapeutics Q4 Earnings
07:39am, Tuesday, 02'nd Mar 2021
Shares of Orchard Therapeutics (NASDAQ:ORTX) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share were up 26.09% year over year to ($0.34), which beat the es
Orchard Therapeutics to Present at Multiple Investor Conferences in March 2021
07:00am, Thursday, 25'th Feb 2021
BOSTON and LONDON, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present at the followin
What's in Store for Orchard Therapeutics (ORTX) Q4 Earnings?
09:15pm, Monday, 15'th Feb 2021
Orchard Therapeutics (ORTX) will provide updates on earnings, revenues of Strimvelis and the pipeline when it releases results for fourth-quarter 2020.
Why Orchard Therapeutics Stock Is Jumping Today
02:32pm, Tuesday, 09'th Feb 2021
The company released some promising data from a pair of proof-of-concept studies.
Orchard Therapeutics' MPS-I Gene Therapy Shows Encouraging Action In Early Study, Shares Spike
08:19am, Tuesday, 09'th Feb 2021
Orchard Therapeutics Plc (NASDAQ: ORTX) gains in premarket in reaction to positive interim data from a proof-of-concept study evaluating its gene therapy OTL-203 in Mucopolysaccharidosis type I (M
